Overview

Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis

Status:
Completed
Trial end date:
2018-02-18
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of two concentrations of PRT-2761 as a topical ophthalmic solution for the treatment of the signs and symptoms of acute and chronic allergic conjunctivitis.
Phase:
Phase 2
Details
Lead Sponsor:
ORA, Inc.
Treatments:
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Olopatadine Hydrochloride
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate